[{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.44,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.44,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Pharmacare Holdings \/ Sandoz"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"","sponsorNew":"Assertio Therapeutics \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera S.A."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical"},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"TRPV1","graph1":"Neurology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Angelini Pharma"},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Approved","graph3":"Burke Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Burke Therapeutics \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Gabapentin","moa":"CaV Channel","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assertio Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ JMP Securities LLC"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"HK Tainuo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omadacycline","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Flexion Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ HK Tainuo","highestDevelopmentStatusID":"12","companyTruncated":"Flexion Therapeutics \/ HK Tainuo"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cove","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cove \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Cove \/ Biohaven"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Orsini Pharmaceutical"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm Services","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Genpharm Services"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Five Leaf Labs","sponsor":"Cannaworx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Phytocannabinoid","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Five Leaf Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Leaf Labs \/ Cannaworx","highestDevelopmentStatusID":"12","companyTruncated":"Five Leaf Labs \/ Cannaworx"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Diclofenac Potassium","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assertio Therapeutics \/ Assertio Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ Assertio Holdings"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Intravaginal","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Millicent Pharma Limited"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ JMP Securities"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"12","companyTruncated":"Prime Therapeutics \/ EMD Serono"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Mylan"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.81999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.81999999999999995,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"NaV Channel","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.80000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Morningside"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"DePuy Synthes Sales Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ DePuy Synthes Sales Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ DePuy Synthes Sales Inc."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Alliance Pharmaceutical Company","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Alliance Pharmaceutical Company \/ Valeo Pharma"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"Il-2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Vizient"},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Galt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Healthcare Solutions \/ Not Applicable"},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIFE SCIENCES LLC \/ Not Applicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Taro Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ Baudax Bio"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Exeltis"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Roche"},{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Alcami","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Alcami \/ Trevena"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisatracurium Besylate","moa":"Nicotinic acetylcholine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Neurology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono \/ Not Applicable"},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIFE SCIENCES LLC \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Eisai"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Athena Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"SPARC \/ Tripoint Therapeutics"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"U.S. Army","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ U.S. Army","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ U.S. Army"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":1.8799999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.8799999999999999,"dosageForm":"Oral prefilled syringe","sponsorNew":"Neuraxpharm \/ Permira Funds","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxpharm \/ Permira Funds"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recipharm AB \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Recipharm AB \/ BIAL"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.22,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.22,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Lobsor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Lobsor Pharmaceuticals \/ STADA"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"European Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ European Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ European Medicines Agency"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Juyou Biotechnology"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sedor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fosphenytoin Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sedor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedor Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"MARATHON PHARMS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Marathon","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Marathon"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ImprimisRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"ImprimisRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Troche","sponsorNew":"ImprimisRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImprimisRx \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas"},{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Sebacate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lumosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rufinamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.95999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.95999999999999996,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Catalent"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"IBSA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Pfizer Inc \/ IBSA","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ IBSA"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PEGASUS LABORATORIES INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Bromide","moa":"Adenosine kinase","graph1":"Neurology","graph2":"Approved","graph3":"PEGASUS LABORATORIES INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Chewable tablet","sponsorNew":"PEGASUS LABORATORIES INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PEGASUS LABORATORIES INC \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ PRA Health Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ PRA Health Sciences"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ S.K Biopharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ S.K Biopharmaceutical"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Lyophilized powder","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":7.2000000000000002,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Durect Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA alpha-1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended release","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Eisai"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","graph1":"Neurology","graph2":"Approved","graph3":"Bened Biomedical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bened Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bened Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Roche"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Series D Financing","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Cormorant Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Luye Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Luye Pharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ PTC therapeutics"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Roche"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ European Pharmaceutical"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AFT Pharmaceuticals \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"Sigma opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":7.2000000000000002,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Morphine Sulfate","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Azathioprine","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Ethypharm"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"J. Wood Capital Advisors LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ J. Wood Capital Advisors LLC","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ J. Wood Capital Advisors LLC"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurimmune \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ UCB"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Eurofarma"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Croma Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Croma Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Roche"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Chugai"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"Ach","graph1":"Neurology","graph2":"Approved","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Teijin Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Edge Pharma","sponsor":"Evio Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cannabis Sativa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Edge Pharma \/ EVIO Labs","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharma \/ EVIO Labs"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Aguettant","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Laboratoire Aguettant","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Laboratoire Aguettant"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oxford Finance LLC","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Oxford Finance LLC"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Spearmint Extract","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Extracts \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alter Pharma group \/ Hyloris","highestDevelopmentStatusID":"12","companyTruncated":"Alter Pharma group \/ Hyloris"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Erenumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ STADA Arzneimittel AG","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ STADA Arzneimittel AG"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Viking Global Investors"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BiArctic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BiArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BiArctic"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ STADA"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Stanford Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Boswellia Serata","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Stanford Medical Center","highestDevelopmentStatusID":"12","companyTruncated":"BioAdaptives \/ Stanford Medical Center"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"MHRA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reckitt Benckiser \/ MHRA","highestDevelopmentStatusID":"12","companyTruncated":"Reckitt Benckiser \/ MHRA"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ultimate Brain Nutrients RELIEF","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Extracts \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor alpha-1A","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion Pharmaceuticals \/ BIAL"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Marigold Extract","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Extracts \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ PPD","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ PPD"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Aurora Cannabis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurora Cannabis \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Pacira","highestDevelopmentStatusID":"12","companyTruncated":"Flexion Therapeutics \/ Pacira"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medolife \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Ionis Pharmaceutical"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":1.24,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.24,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Erenumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","graph1":"Neurology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co., Ltd.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co., Ltd."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Biohaven"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"ICURE PHARM, INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"ICURE PHARM, INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ICURE PHARM, INC \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Prothrombin","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Aspirin","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Bayer AG","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp I","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.6399999999999999,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Co.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"Avicanna","sponsor":"Harrington Wellness","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Avicanna \/ Harrington Wellness","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Harrington Wellness"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Avicanna","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1","graph1":"Neurology","graph2":"Approved","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Knopp Biosciences LLC \/ Avicanna","highestDevelopmentStatusID":"12","companyTruncated":"Knopp Biosciences LLC \/ Avicanna"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":1.24,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.24,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Neurelis","highestDevelopmentStatusID":"12","companyTruncated":"Aculys Pharma \/ Neurelis"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"ET receptor","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Diclofenac","moa":"COX-1\/COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sustained Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Novartis"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Riluzole","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ UCB"},{"orgOrder":0,"company":"Trupharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trupharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Trupharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trupharma \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Brain Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Brain Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Brain Therapeutics \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Brain Therapeutics \/ Neuraxpharm Group"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Bioarctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bioarctic"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Oaktree Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"AchE","graph1":"Neurology","graph2":"Approved","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Corium"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Seton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Seton Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirogabalin Besylate","moa":"CaV1\/CaV2 Channel","graph1":"Neurology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Collegium"},{"orgOrder":0,"company":"Sciensus Rare","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Sciensus Rare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sciensus Rare \/ MGC Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sciensus Rare \/ MGC Pharma"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","graph1":"Neurology","graph2":"Approved","graph3":"Bened Biomedical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bened Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bened Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Avet Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avet Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSN Laboratories \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MSN Laboratories \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Octavius Pharma Pvt. Ltd","sponsor":"Senta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Menthol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Octavius Pharma Pvt. Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Octavius Pharma Pvt. Ltd \/ Senta Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Octavius Pharma Pvt. Ltd \/ Senta Pharma"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"AiPing Pharmaceutical Inc","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"AiPing Pharmaceutical Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biopas Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"MAO","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Biopas Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Biopas Laboratories"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Neuraxpharm Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Takeda Pharmaceutical \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Neuraxpharm Group"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxpharm \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Lorraine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Crocus Sativus","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Silvanols \/ University of Lorraine","highestDevelopmentStatusID":"12","companyTruncated":"Silvanols \/ University of Lorraine"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Catalent"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Approved","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"PG G\/H synthase 1","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Crescita Therapeutics \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Egis Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Intramuscular injection","sponsorNew":"Crossject \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ BARDA"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"Decarboxylase","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/ PANTHERx Rare"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial injection","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Eurofarma"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Boswellia Serata","moa":"COX2","graph1":"Neurology","graph2":"Approved","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioAdaptives \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Hospira, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hospira, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eton Pharmaceuticals \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Azurity Pharmaceuticals"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Allergan","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Allergan"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"Ach","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius SE & Co. KGaA \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Adalvo"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Brand Institute"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"CH Trading Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ CH Trading Group","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ CH Trading Group"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zinc Sulphate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Piramal Pharma Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Piramal Pharma Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rufinamide","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hospira, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Collegium Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Tsukuba Research Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Tsukuba Research Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Tsukuba Research Laboratories"},{"orgOrder":0,"company":"Rafa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Rafa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rafa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rafa \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"SCN10A","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab-vfrm","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ubrogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"ACh","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Stiripentol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"SCN10A","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Medytox","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medytox \/ Bloomage BioTechnology","highestDevelopmentStatusID":"12","companyTruncated":"Medytox \/ Bloomage BioTechnology"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":11.6,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":11.6,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Acquisitions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Approved","graph3":"Omeros","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Solution","sponsorNew":"Omeros \/ DRI Healthcare Acquisitions","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ DRI Healthcare Acquisitions"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.25,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clobazam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cocaine Hydrochloride","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Beta-1a","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"ACh receptor","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rufinamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Eperisone Hydrochloride","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ DKSH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Reakiro","sponsor":"A2W Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Reakiro","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Reakiro \/ A2W Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Reakiro \/ A2W Pharma"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phenobarbital Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kirin \/ Grunenthal"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Catalent Pharma Solutions \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Yaral Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yaral Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"LGS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ LGS Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ LGS Foundation"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Salus Pharmaceuticals \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phenobarbital Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Difluprednate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine Hydrochloride","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ UCB Pharma S.A"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":11.6,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":11.6,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Scilex Holding Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Undisclosed \/ Scilex Holding Company","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Scilex Holding Company"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ AffaMed Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Quimica \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxcarbazepine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aucta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.47999999999999998,"dosageForm":"Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cantone Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Rizatriptan Benzoate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Cantone Research","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Cantone Research"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ YA II PN","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ YA II PN"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Atnahs Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Atnahs Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Atnahs Pharma"},{"orgOrder":0,"company":"Entourage Health","sponsor":"NordicCan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Entourage Health \/ NordicCan","highestDevelopmentStatusID":"12","companyTruncated":"Entourage Health \/ NordicCan"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"SINTETICA SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SINTETICA SA \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dichlorphenamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Torrent Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ Not Applicable"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Aksigen Hospital Care","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Bromelain","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aksigen Hospital Care","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tetra Pharm Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tetra Pharm Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Acorda Therapeutics \/ Chance Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Chance Pharmaceuticals"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Pfizer Inc \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zenara Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zenara Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methsuximide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Yaral Pharma"},{"orgOrder":0,"company":"Trevena","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Farouk, Maamoun Tamer & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co."},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rocuronium Bromide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi USA \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Applied Research Centre at Langara College"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Galcanezumab-gnlm","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Akums Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Somalab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Somalab","highestDevelopmentStatusID":"12","companyTruncated":"Pressure BioSciences \/ Somalab"},{"orgOrder":0,"company":"Avicanna","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Medipharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Medipharm Labs"},{"orgOrder":0,"company":"HempMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HempMeds \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oxcarbazepine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"C2N Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ C2N Diagnostics","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ C2N Diagnostics"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Crossject","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Sosei Heptares","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Pharmaceuticals \/ Sosei Heptares"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ublituximab-xiiy","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"Grunenthal Meds","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Grunenthal Meds","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Grunenthal Meds \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal Meds \/ Grunenthal"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Genixus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rocuronium Bromide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Genixus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genixus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genixus \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab-sztn","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Polpharma","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Polpharma"},{"orgOrder":0,"company":"Trevena","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ CBC Group"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Oberon Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MGC Pharmaceuticals \/ Oberon Capital","highestDevelopmentStatusID":"12","companyTruncated":"MGC Pharmaceuticals \/ Oberon Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Gensco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Gensco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Gensco Pharma"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Slayback Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Slayback Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab-sztn","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Gensco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Gensco Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Gensco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gensco Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Tilray"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Premier","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Premier \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ Trevena"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Ponesimod","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"CrossLink Life Sciences","sponsor":"Heron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Bupivacaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"CrossLink Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"CrossLink Life Sciences \/ Heron Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CrossLink Life Sciences \/ Heron Therapeutics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Talphera","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Talphera","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Talphera \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Talphera \/ XOMA"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Natalizumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronidase","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akumentis Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akumentis Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Crist\u00e1lia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Crist\u00e1lia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ Crist\u00e1lia"},{"orgOrder":0,"company":"Sipp Industries","sponsor":"SinuSave","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sipp Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sipp Industries \/ SinuSave","highestDevelopmentStatusID":"12","companyTruncated":"Sipp Industries \/ SinuSave"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurimmune","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Neurimmune \/ Biogen"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Myung In Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Myung In Pharm"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Zambon Group Spa","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Zambon Group Spa"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Gensci"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Exeltis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Patch","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Almirall"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Gensci"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Gensci"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmascience Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Aucta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Crossject","sponsor":"Heights Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Heights Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Heights Capital Management"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Ublituximab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Baclofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sycamore BioPharma","sponsor":"Branded Legacy, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sycamore BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Sycamore BioPharma \/ Branded Legacy, Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sycamore BioPharma \/ Branded Legacy, Inc"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ponesimod","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Juvise Pharmaceuticals"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akums Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Pacira BioSciences \/ Premier"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Akumentis Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akumentis Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Corticotropin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Cipla","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cipla \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Sanofi"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"HANDOK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Handok","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Handok"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Baclofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Nika Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Galantamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Atogepant","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zonisamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Towa Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Towa Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazepam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Patisiran","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Gemmes Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Gemmes Venture","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Gemmes Venture"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Adalvo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ Not Applicable"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Anglo-French Drugs and industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Anglo-French Drugs and industries \/ Not Applicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Remedies Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofersen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"B. Braun Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"B. Braun Medical \/ Not Applicable"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Teikoku Pharma USA \/ Link Healthcare Group","highestDevelopmentStatusID":"12","companyTruncated":"Teikoku Pharma USA \/ Link Healthcare Group"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Magnesium Sulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Angelini Pharma"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ponesimod","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Pharmaceuticals \/ Not Applicable"}]
Find Approved Neurology Drugs in Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
